This is a repository copy of Conceptual modelling for health economic model development.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/74464/

Article:

Reuse
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Conceptual Modelling For Health Economic Model Development

Tappenden, P

1. Health Economics and Decision Science, School of Health and Related Research, University of Sheffield
2. Department of Economics, University of Sheffield

Disclaimer:
This series is intended to promote discussion and to provide information about work in progress. The views expressed in this series are those of the authors, and should not be quoted without their permission. Comments are welcome, and should be sent to the corresponding author.

White Rose Repository URL for this paper: http://eprints.whiterose.ac.uk/74464

White Rose Research Online
eprints@whiterose.ac.uk
CONCEPTUAL MODELLING FOR HEALTH ECONOMIC MODEL DEVELOPMENT

Author
Dr Paul Tappenden, Senior Research Fellow, ScHARR, Regent Court, 30 Regent Street, University of Sheffield, Sheffield, S1 4DA; Tel: +44 114 2220855; Fax: +44 114 2724095
Email: p.tappenden@sheffield.ac.uk

Acknowledgements
The general framework presented within this paper has been adapted from a Technical Support Document funded by the National Institute for Health and Clinical Excellence to support their Technology Appraisal Programme. The views expressed within this paper reflect those of the authors and do not necessarily reflect those of NICE. Thanks to Alec Miners, Luke Vale, Rob Anderson, Suzy Paisley, Eva Kaltenthaler, Chris Hyde and Stewart Robinson for their useful comments on draft versions of this manuscript.
## Glossary

| **Problem structuring methods** | A set of formal methods developed within the field of Operational Research intended to develop consensus, structure and make sense of complex or messy problems. |
| **Conceptual model** | The abstraction and representation of complex phenomena of interest in some readily expressible form, such that individual stakeholders’ understanding of the parts of the actual system, and the mathematical representation of that system, may be shared, questioned, tested and ultimately agreed. |
| **Problem-oriented conceptual model** | A form of conceptual model which is developed to understand the decision problem and the system in which that problem exists. |
| **Design-oriented conceptual model** | Conceptual models which are focussed on the consideration of alternative potentially acceptable and feasible quantitative model designs, to specify the model’s evidence requirements and to provide a basis for comparison and justification against the final implemented model. |
| **Disease process model** | A problem-oriented conceptual model which sets out the disease-specific events and processes within the system in which the decision problem exists. |
| **Service pathways model** | A problem-oriented conceptual model which sets out the elements of the service which are relevant to the system in which the decision problem exists. |

## Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>HRQoL</td>
<td>Health-related quality of life</td>
</tr>
<tr>
<td>HTA</td>
<td>Health Technology Assessment</td>
</tr>
<tr>
<td>NICE</td>
<td>National Institute for Health and Clinical Excellence</td>
</tr>
<tr>
<td>PSMs</td>
<td>Problem Structuring Methods</td>
</tr>
<tr>
<td>QALY</td>
<td>Quality adjusted life year</td>
</tr>
<tr>
<td>SODA</td>
<td>Strategic Options Development and Analysis</td>
</tr>
<tr>
<td>SSM</td>
<td>Soft Systems Methodology</td>
</tr>
</tbody>
</table>
Introduction
Health economic evaluation is a general framework for informing decisions about whether particular health technologies represent a cost-effective use of health care resources. Commonly, the evidence required to inform a decision about the cost-effectiveness of a given set of competing health technologies is not available from a single source. The use of mathematical modelling can be used to support this decision-analytic framework thereby allowing the full range of relevant evidence to be synthesised and brought to bear on the decision problem.\(^1\) The process of developing a decision-analytic model is generally seen as being iterative, and requires the model developer to make a substantial number of choices about what should be included in a model and how these included phenomena should be related to one another. These choices take place at every stage of the model development process, and include choices about the comparators to be assessed, choices about which health states and sequences of events will comprise the model’s structure, choices about which evidence sources should be used to inform the model parameters, and choices about statistical methods for deriving the model’s parameters, to name but a few. Importantly the absence of perfect information through which to comprehensively validate a model means that there is rarely a definitive means through which to prospectively determine whether these choices are right or wrong. Instead, model development choices are made on the basis of subjective judgements, with the ultimate goal of developing a model which will be useful in informing the decision at hand.

Therefore, model development is perhaps best characterised as a complex process in which the modeller, in conjunction with other stakeholders, determines what is relevant to the decision problem (and at the same time, what can reasonably be considered irrelevant to the decision problem). This notion of relevance has a direct bearing on the credibility of a model and on the interpretation of results generated using that model. Failure to account for the complexities of the decision problem may result in the development of models which are “mathematically sophisticated but contextually naïve.”\(^2\) The development of useful mathematical models therefore requires more than mathematical ability alone: it firstly requires the model developer to understand the complexity of the real system that the model will attempt to represent, and the choices available for translating this understanding of complexity into a credible conceptual and mathematical structure. It is perhaps surprising that whilst much has been written about the technical aspects of model development, for example the statistical extrapolation of censored data and methods for synthesising evidence from multiple sources, there is a comparative dearth of practical guidance surrounding formal processes through which an appropriate model structure should be determined. It is this complex and messy subject matter that forms the focus of this paper.

The purpose of this paper is not to rigidly prescribe how model development decisions should be made, nor is it intended to represent a comprehensive guide of “how to model.” The former would
undoubtedly fail to reflect the unique characteristics of each individual decision problem and could
discourage the development of new and innovative modelling methods. Conversely, the latter would
inevitably fail to reflect the sheer breadth of decisions required during model development. Rather,
the purposes of this paper are threefold:

(1) To highlight that structural model development choices invariably exist;
(2) To suggest a generaliseable and practical hierarchical approach through which these
alternative choices can be prospectively exposed, considered and assessed, and;
(3) To highlight key issues and caveats associated with the use of certain types of evidence in
informing the conceptual basis of the model.

The paper is set out as follows. The paper begins by introducing concepts surrounding the role and
interpretation of mathematical models in general, and attempts to highlight the importance of
conceptual modelling within the broader model development process. Following on from this,
existing literature surrounding model structuring and conceptual modelling is briefly discussed. The
paper then moves on to suggest a practicable framework for understanding the nature of the decision
problem to be addressed in order to move towards a credible and acceptable final mathematical model
structure. A series of potentially useful considerations is presented to inform this process.

The interpretation of mathematical models
A mathematical model is a “representation of the real world... characterised by the use of
mathematics to represent the parts of the real world that are of interest and the relationships between
those parts.”3 The roles of mathematical modelling are numerous, including extending results from a
single trial, combining multiple sources of evidence, translating from surrogate/intermediate
endpoints to final outcomes, generalising results from one context to another, informing research
planning and design, and characterising and representing decision uncertainty given existing
information.4 At a broad level, mathematical or simulation models in Health Technology Assessment
(HTA) are generally used to simulate the natural history of a disease and the impact of particular
health technologies upon that natural history in order to estimate incremental costs, health outcomes
and cost-effectiveness.

All mathematical models require evidence to inform their parameters. Such evidence may include
information concerning disease natural history or baseline risk of certain clinical events,
epidemiology, resource use and service utilisation, compliance/participation patterns, costs, health-
related quality of life (HRQoL), survival and other time-to-event outcomes, relative treatment effects
and relationships between intermediate and final endpoints. However, the role of evidence is not
restricted to informing model parameters. Rather, it is closely intertwined with questions about which
model parameters should be considered relevant in the first place and how these parameters should be
characterised. The consideration of how best to identify and use evidence to inform a particular model parameter thus firstly requires an explicit decision that the parameter in question is “relevant”, the specification or definition of that parameter, and some judgement concerning its relationship to other “relevant” parameters included in the model. This often complex and iterative activity is central to the process of model development and can be characterised as a series of decisions concerning (a) what should be included in the model, (b) what should be excluded, and (c) how those phenomena that are included should be conceptually and mathematically represented.

The need for these types of decisions during model development is unavoidable, rather it is a fundamental characteristic of the process itself. Whilst this activity already takes place in health economic model development, it is often unclear how this process has been undertaken and how this may have influenced the final implemented model. In practice, the reporting of model structures tends to be very limited and, if present, usually focuses only on the final model that has been implemented. In such instances, the reader may be left with little idea about whether or why the selected model structure should be considered credible, which evidence has been used to inform its structure, why certain abstractions, simplifications and omissions have been made, why certain parameters were selected for inclusion (and why others have been excluded), and why the included parameters have been defined in a particular way. This lack of systematicity and transparency ultimately means that judgements concerning the credibility of the model in question may be difficult to make. In order to produce practically useful guidance concerning the use of evidence in models, it is firstly important to be clear about the interpretation of abstraction, bias and credibility in the model development process.

i) Credibility of models
A model cannot include every possible relevant phenomena; if it could it would no longer be a model but would instead be the real world. The value of simplification and abstraction within models is the ability to examine phenomena which are complex, unmanageable or otherwise unobservable in the real world. As a direct consequence of this need for simplification, all models will be, to some degree, wrong. The key question is not whether the model is “correct” but rather whether it can be considered to be useful for informing the decision problem at hand. This usefulness is directly dependent upon the credibility of the model’s results, which is, in turn, hinged upon the credibility of the model from which those results are drawn. Owing to the inevitability of simplification and abstraction within models, there is no single “perfect” or “optimal” model. There may however exist one or more “acceptable” models; even what is perceived to be the “best” model could always be subjected to some degree of incremental improvement (and indeed the nature of what constitutes an improvement requires some subjective judgement). The credibility of potentially acceptable models can be assessed and differing levels of confidence can be attributed to their results on the basis of such judgements. The level of confidence given to the credibility of a particular model may be determined.
retrospectively – through considerations of structural and methodological uncertainty ex post facto, or prospectively – through the a priori consideration of the process through which decisions are made concerning the conceptualisation, structuring and implementation of the model.

ii) Defining relevance in models
The purpose of models is to represent reality, not to reproduce it. The process of model development involves efforts to reflect those parts of reality that are considered relevant to the decision problem. Judgements concerning relevance may differ between different modellers attempting to represent the same part of reality. The question of “what is relevant?” to a particular decision problem should not be judged solely by the individual developing the model; rather making such decisions should be considered as a joint task between modellers, decision-makers, health professionals and other stakeholders who impact upon or are impacted upon by the decision problem under consideration. Failure to reflect conflicting views between alternative stakeholders may lead to the development of models which represent a contextually naïve and uninformed basis for decision-making.

iii) The role of clinical/expert input
Clinical opinion is essential in understanding the relevant facets of the system in which the decision problem exists. This clinical opinion is not only relevant, but essential, because it is sourced from individuals who interact with this system in a way that a modeller cannot. This information forms the cornerstone of a model’s contextual relevance. However, it is important to recognise that health professionals cannot fully detach themselves from the system in which they practise; their views of a particular decision problem may be to some degree influenced by evidence they have consulted, their geographical location, local enthusiasms, their experience and expertise, together with a wealth of other factors. Understanding why the views of stakeholders differ from one another is important, especially with respect to highlighting geographical variations. As such, the use of clinical input in informing models and model structures brings with it the potential for bias. Bias may also be sourced from the modeller themselves as a result of their expertise, their previous knowledge of the system in which the current decision problem resides, and the time and resource available for model development. Where possible, potential biases should be brought to light to inform judgements about a model’s credibility.

Problem-structuring in health economics and other fields
It is important at this stage to note that whilst related to one another, there is a distinction between problem structuring methods (PSMs) and methods for structuring models. The former are concerned with understanding the nature and scope of the problem to be addressed, eliciting different stakeholders’ potentially conflicting views of the problem and developing consensus, exploring what potential options for improvement might be available, and even considering whether a problem exists
at all. There exist a number of methods to support this activity which have emerged from the field of “soft” Operational Research; these include Strategic Options Design and Analysis (SODA) and cognitive mapping, Soft Systems Methodology (SSM), Strategic Choice Approach and Drama Theory to name but a few. All stakeholders are seen as active “problem owners” and each of their views are considered important. The emphasis of PSMs is not to identify the “rationally optimal” solution, but rather to lay out the differing perceptions of the problem owners to foster discussion concerning potential options for improvement to the system. The value or adequacy of the PSMs is gauged according to whether they usefully prompt debate, with the intended endpoint being some agreement about the structure of the problem to be addressed and the identification and agreement of potential improvements to that problem situation. They do not necessarily assume that a mathematical model is appropriate or required. These methods are not discussed further here, but the interested reader is directed to the excellent introductory text by Rosenhead and Mingers.6

Conversely, formal methods for model structuring, which relates principally to developing a conceptual basis for the quantitative model, remain comparatively under-developed, both in the context of health economic evaluation as well as in other fields. A recent review of existing conceptual modelling literature7 concluded that whilst conceptual modelling is “probably the most important element of a simulation study”, there remains for the most part, a vacuum of research in terms of what conceptual modelling is, why it should be done, and how it may be most effectively implemented. Where formal conceptual modelling viewpoints have emerged, there is little consensus or consistency concerning how this activity should be approached.

This problem is particularly applicable in the field of health economics. Recently, a qualitative research study was undertaken to examine techniques and procedures for the avoidance and identification of errors in HTA models.8 Interviewees included modellers working within Assessment Groups involved in supporting NICE’s Technology Appraisal Programme as well as those working for outcomes research groups involved in preparing submissions to NICE on behalf of pharmaceutical companies. A central aspect of these interviews involved the elicitation of a personal interpretation of how each interviewee develops models. These descriptions were synthesised to produce a stylised model development process, comprising five broad bundles of activities (see Box 1 and Figure 1).
Box 1: Main stages in the model development process (adapted from Chilcott et al)

1. **Understanding the decision problem:** Activities including immersion in research evidence, defining the research question, engaging with clinicians, decision-makers and methodologists, and understanding what is feasible.

2. **Conceptual modelling:** Activity related to translating the understanding of the decision problem towards a mathematical model-based solution.

3. **Model implementation:** Implementation of the model within a software platform.

4. **Model checking:** Activity to avoid and identify model errors. This includes engaging with experts, checking face validity, testing values, structure and logic, checking data sources etc.

5. **Engaging with decision:** Model reporting and use by the decision-maker(s).

Figure 1: Stylised model development process

One particular area of variability between interviewees concerned their approaches to conceptual model development. During the interviews, respondents discussed the use of several approaches to conceptual modelling including documenting proposed model structures, developing mock-up models in Microsoft Excel, developing sketches of potential structures, and producing written interpretations of evidence. For several respondents, the model development process did not involve any explicit conceptual modelling activity; in these instances, the conceptual model and implementation model
were developed in parallel with no discernable separation between the two activities. This is an important distinction to make with respect to model credibility and validation (as discussed below) and the processes through which evidence is identified and used to inform the final implemented model.

**Definition and purpose of conceptual modelling**

Whilst others have recognised the importance of conceptual modelling as a central element of the model development process, it has been noted that this aspect of model development is probably the most difficult to undertake and least well understood.\(^7,9\) Part of the problem stems from inconsistencies in the definition and the role(s) of conceptual modelling, and more general disagreements concerning how such activity should be used to support and inform implementation modelling. The definition and characteristics of conceptual modelling are dependent on the perceived purposes of the activity. For the purpose of this document, conceptual modelling is taken as: “the abstraction and representation of complex phenomena of interest in some readily expressible form, such that individual stakeholders’ understanding of the parts of the actual system, and the mathematical representation of that system, may be shared, questioned, tested and ultimately agreed.”

Whilst there is inevitable overlap associated with processes for understanding the decision problem to be addressed, conceptual modelling is distinguishable from these activities in that it is targeted at producing tangible outputs in the form of one or more conceptual models. In the context of health economic evaluation, conceptual model development may be used to achieve a number of ends, as highlighted in Box 2. Broadly speaking, these roles fall into two groups: (1) those associated with developing, sharing and testing one’s understanding of the decision problem and the system in which this exists, and (2) those associated with designing, specifying and justifying the model and its structure. Therefore it seems sensible to distinguish between problem-oriented conceptual models and design-oriented conceptual models; this distinction has been made elsewhere outside of the field of health economics.\(^10\) The characteristics of these alternative types of conceptual model are briefly detailed below. Both of these types of model may be useful approaches for informing the relevant characteristics of a health economic model.
Box 2: The roles of conceptual modelling in health economic model development

<table>
<thead>
<tr>
<th>Problem-oriented conceptual models</th>
</tr>
</thead>
<tbody>
<tr>
<td>• To ensure that health professionals understand how the model will capture the impact of the interventions under consideration on costs and health outcomes</td>
</tr>
<tr>
<td>• To ensure that the proposed model will be clinically relevant - that all relevant events, resources, costs and health outcomes have been included and that these reflect current knowledge of disease and treatment systems</td>
</tr>
<tr>
<td>• To ensure that the proposed model will meet the needs of the decision-maker</td>
</tr>
<tr>
<td>• To provide a reference point during model implementation</td>
</tr>
<tr>
<td>• To highlight uncertainty and variation between healthcare practitioners</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Design-oriented conceptual models</th>
</tr>
</thead>
<tbody>
<tr>
<td>• To provide a common understanding amongst those involved in model development regarding model evidence requirements prior to model implementation</td>
</tr>
<tr>
<td>• To provide an explicit platform for considering and debating alternative model structures and other model development decisions prior to implementation (including the a priori consideration of structural uncertainties)</td>
</tr>
<tr>
<td>• To provide a reference point during model implementation</td>
</tr>
<tr>
<td>• To provide the conceptual basis for reporting the methods and assumptions employed within the final implemented model</td>
</tr>
<tr>
<td>• To provide a basis for comparison and justification of simplifications and abstractions during model development</td>
</tr>
</tbody>
</table>

**Problem-oriented conceptual models:** This form of conceptual model is developed to understand the decision problem and the system in which that problem exists. The focus of this model form concerns fostering communication and understanding between those parties involved in informing, developing, and using the model. In health economic evaluation, this type of conceptual model is primarily concerned with developing and agreeing a description of the disease and treatment systems: (a) to describe the current clinical understanding of the relevant characteristics of the disease process(es) under consideration and important events therein, and; (b) to describe the clinical pathways through which patients with the disease(s) are detected, diagnosed, treated and followed-up. This type of conceptual model is therefore solely concerned with unearthing the complexity of the decision problem and the system in which it exists; its role is not to make assertions about how those relevant aspects of the system should be mathematically represented. The definition of “what is
relevant?” for this type of conceptual model is thus primarily dependent on expert input rather than
the availability of empirical research evidence. In this sense, this type of conceptual model is a
problem-led method of enquiry.

Design-oriented conceptual models: This form of conceptual model is focussed on the consideration
of alternative potentially acceptable and feasible quantitative model designs, to specify the model’s
anticipated evidence requirements, and to provide a basis for comparison and justification against the
final implemented model. In order to achieve these ends, it draws together the problem-oriented
conceptual views of relevant disease and treatment processes and interactions between the two. The
design-oriented conceptual model sets out a clear boundary around the model system, defines its
breadth (how far down the model will simulate certain pathways for particular patients and
subgroups) and sets out the level of depth or detail within each part of the model. It therefore
represents a platform for identifying and thinking through potentially feasible and credible model
development choices prior to actual implementation. Within this context, the definition of “what is
relevant?” is guided by the problem-oriented models and therefore remains problem-led, but is
mediated by the question of “what is feasible?” given the availability of existing evidence and model
development resources (available time, money, expertise etc.).

Conceptual modelling activity, however defined, is directly related to model credibility and
validation. The absence of an explicit conceptual model means that a specific point of model
validation is lost. As a model cannot include everything, an implemented model is inevitably a subset
of the system described by the problem-oriented conceptual model. This hierarchical separation
allows simplifications and abstractions represented in the implemented model to be compared against
its conceptual counterpart, thereby allowing for debate and justification. However, in order to make
such comparisons, conceptual model development must be overt: the absence or incomplete
specification of a conceptual model leads to the breakdown of concepts of model validation and
verification. Without first identifying and considering the alternative choices available, it is
impossible to justify the appropriateness of any particular model. Further, without first setting out
what is known about the relevant disease and treatment processes, the extent or impact of particular
assumptions and simplifications cannot be drawn out explicitly. Therefore, the benefit of separating
out conceptual modelling activity into distinct problem-oriented and design-oriented components is
that this allows the modeller (and other stakeholders) to firstly understand the complexities of the
system the model intends to represent, and then to examine the extent to which the simplifications and
abstractions resulting from alternative “hard” model structures will deviate from this initial view of
the system. Figure 2 shows the hierarchical relationship between the real world, the problem- and
design-oriented conceptual models and the final implemented model.
Figure 2: A hierarchy of models

Practical approaches to conceptual modelling in HTA
This section suggests how conceptual modelling could be undertaken and which elements of model development activity should be reported. Practical considerations surrounding conceptual model development are detailed below with reference to a purposefully simple model to assess the cost-effectiveness of adjuvant treatments for a hypothetical cancer area. These considerations are intended to be broadly generalisable to economic analysis within other diseases and conditions. It should be noted that the illustrative model is only intended to suggest how the alternative conceptual models forms may be presented and used. The problem-oriented model is divided into two separate conceptual model views; a disease process model and a service pathways model.

Problem-oriented conceptual modelling - disease process models
Figure 3 presents a simple example of a conceptual disease process model for the hypothetical decision problem. The focus of this type of model is principally on relevant disease events and processes rather than on the treatments received. At each point in the pathway, the focus should therefore relate to an individual patient’s true underlying state rather than what is known by healthcare professionals at a particular point in time. It should be reiterated that this type of conceptual model does not impose or imply any particular decision concerning modelling methodology or appropriate outcome measures; it is solely a means of describing the relevant clinical events and processes within the system of interest. It should also be noted that such conceptual models should be accompanied by textual descriptions to support their interpretation and to capture any factors or complexities which are not represented diagrammatically.
The following non-exhaustive set of issues and considerations may be useful when developing and reporting this type of problem-oriented conceptual model:

**Inclusion/exclusion of disease-related events**

- What are the main relevant events from a clinical/patient perspective? Does the conceptual model include explicit reference to all clinically meaningful events? For example, could a patient experience local relapse? Or could the intervention affect other diseases (e.g. late secondary malignancy resulting from radiation therapy used to treat the primary tumour)?

- Can these relevant events be discretised into a series of mutually exclusive biologically plausible health states? Does this make the process easier to explain?
  - If so, which metric would be clinically meaningful or most clinically appropriate?
    - Which discrete states would be clinically meaningful? How do clinicians think about the disease process? How do patients progress between these states or sequences of events?
  - If not, how could the patient’s preclinical trajectory be defined?

- Do alternative staging classifications exist, and if so can/should they be presented simultaneously?

- Are all relevant competing risks (e.g. relapse or death) considered?

- For models of screening or diagnostic interventions, should the same metric used to describe preclinical and post-diagnostic disease states?

- Is the breadth of the conceptual model complete? Does the model represent all relevant states or possible sequences of events over the relevant patient subgroups lifetime?

- What are the causes of death? When can a patient die from these particular causes? Can patients be cured? If so, when might this happen and for which states does this apply? What is the prognosis for individuals who are cured?
Impact of the disease on HRQoL and other outcomes

- Is there a relationship between states, events and HRQoL? Which events are expected to impact upon a patient’s HRQoL?
- Does the description of the disease process capture separate states in which a patient’s HRQoL is likely to be different?
- Does the description of the disease process capture different states for prognosis?

Representation of different-risk subgroups

- Is it clear which competing events are relevant for particular subgroups?
- Does the description of the disease process represent a single patient group or should it discriminate between different subgroups of patients?
- Are these states/events likely to differ by patient subgroup?

Impact of the technology on the conceptualised disease process

- Have all competing technologies relevant to the decision problem been identified?
- Can the conceptual model be used to explain the impact(s) of the technology or technologies under assessment? Do all technologies under consideration impact upon the same set of outcomes in the same way?
- Are there competing theories concerning the impact(s) of the technology upon the disease process? Can these be explained using the conceptual model?
- Does the use of the health technology result in any other impacts upon health outcomes that cannot be explained using the conceptual disease process model?

Problem-oriented conceptual modelling – service pathways models

Figure 4 presents an illustrative service pathways model for the hypothetical decision problem. In contrast to the disease process model, the focus of the service pathways model is principally concerned with the health care interventions received based upon what is known or believed by healthcare practitioners at any given point in time. Again, such conceptual models should be accompanied by textual descriptions to ensure clarity in their interpretation and to retain any complexity which is not or cannot be captured diagrammatically.
Figure 4: Illustrative service pathways model

Patient dies during initial adjuvant chemotherapy period

Patient survives surgery - returns to follow-up (same schedule but surgeon-led, potential complications)

Patient dies during follow-up

Death

IP – inpatient; OP - outpatient
The following issues and considerations may be useful when developing and reporting this type of conceptual model:

**Relationship between risk factors, prognosis and service pathways**
- Is it clear where and how patients enter the service? Is it clear where patients leave the service (either through discharge or death)?
- Does the model make clear which patients follow particular routes through the service?
- Are any service changes occurring upstream in the disease service which may influence the casemix of patients at the point of model entry? E.g. if surgical techniques were subject to quality improvement might this change patient prognosis further downstream in the pathway?
- Does the model highlight the potential adverse events resulting from the use of particular interventions throughout the pathway? What are these? Do they apply to all competing technologies under consideration?
- Are there any potential feedback loops within the system (e.g. resection→follow-up→relapse→re-resection→follow-up)?
- Which patients receive active treatment and which receive supportive care alone? What information is used to determine this clinical decision (e.g. fitness, patient choice)?

**Distinction between what is true and what is known**
- How does the pathway change upon detection of the relevant clinical events, as defined in the conceptual disease process model? For example, at what point may relapse be detected?
- Is the occurrence of certain events likely to be subject to interval censoring?

**Geographical variations**
- How do the service pathways represented in the model likely to vary by geographical location or local enthusiasms? What are these differences and which parts of the pathway are likely to be affected most?

**Nature of resource use**
- What are the relevant resource components across the pathway and what is the nature of resource use at each point of intervention? E.g. routine follow-up dependent on relapse status, once-only surgery (except for certain relapsing patients), cycle-based chemotherapy, doses dependent on certain characteristics, dose-limited radiation treatment etc.
- Does the conceptual service pathways model include all relevant resource components?
- Which resources are expected to be the key drivers of costs?

**Impact of the technology on the service pathway**
- Which elements of the conceptual model will the intervention under assessment impact upon? E.g. different costs of adjuvant treatment, different mean time in follow-up, different numbers of patients experiencing metastatic relapse? What are expected to be the key drivers of costs?
Box 3 presents recommendations for developing and reporting problem-oriented conceptual models.

**Box 3: Recommendations for practice – problem-oriented models**

| (1) | Develop the structure of the problem-oriented conceptual model using clinical guidelines and health professionals |
| (2) | Use other health professionals not involved in model development to provide peer review and to check understanding of the conceptual models |
| (3) | The precise graphical approach for presenting the conceptual models is important only in that they should be easily understood by health professionals and other decision stakeholders |
| (4) | For the sake of clarity, it may be beneficial to present the model in both diagrammatic and textual forms using non-technical, non-mathematical language |
| (5) | Develop the problem-oriented models before developing the design-oriented model. The feasibility and acceptability of the design-oriented conceptual model should have no bearing on the adequacy of the problem-oriented conceptual models. |

**Practical considerations – design-oriented conceptual models**

Figure 5 presents an example of a design-oriented conceptual model for the hypothetical decision problem. Again, note that this is not intended to represent the “ideal” model but merely illustrates the general approach; there could be a number of design-oriented conceptual models that may be considered credible and acceptable by those parties using the model. This type of model draws together the problem-oriented model views with the intention of providing a platform for considering and agreeing structural model development decisions. By following this general conceptual approach it should be possible to identify the anticipated evidence requirements for the model at an early stage in model development.

Anticipated evidence requirements to populate the proposed illustrative model are likely to include the following types of information:

- Time-to-event data to describe sojourn time/event rates and competing risks in States 1-4 for the current standard treatment
- Relative effect estimates for the intervention(s) versus comparator (e.g. hazard ratios or independent hazards time-to-event data)
- Information relating to survival following cure
- HRQoL utilities for cancer and cured states
- Estimates of QALY losses or utility decrements and duration data for adverse events
- Information concerning the probability that a relapsed patient undergoes active/palliative treatment
• Survival and other time-to-event outcomes for relapsed patients
• Resource use and costs associated with:
  o Chemotherapy (drug acquisition, administration, pharmacy/dispensing, drugs to manage adverse events, line insertion)
  o Resource use and unit costs for follow-up
  o Supportive care following relapse
  o Active treatments following relapse

It may be helpful to consider the following issues when developing design-oriented conceptual models.

Anticipated evidence requirements

• What clinical evidence is likely to be available through which to simulate the impact of the new intervention(s)? How should these parameters be defined and what alternatives are available? Should independent or proportional hazards be assumed?
• Are all relevant interventions and comparators compared within the same trial? If not, is it possible for outcomes from multiple trials to be synthesised? How will this be done?
• What evidence is required to characterise adverse events within the model? What choices are available?
• Beyond the baseline and comparative effectiveness data relating to the technology itself, what other outcomes data will be required to populate the downstream portions of the model (e.g. progression-free survival and overall survival by treatment type for relapsed patients, survival duration in cured patients)?
• Will any intermediate-final relationships be modelled? What external evidence is there to support such relationships? What are the uncertainties associated with this approach and how might these be reflected in the model?
• Which descriptions of HRQoL states are possible and how will these parameters be incorporated into the final model?
• Will all model parameters be directly informed by evidence or will calibration methods (e.g. Markov Chain Monte Carlo) be required? Which calibration methods will be used and why should these be considered optimal or appropriate?
• What pre-model analysis will be required to populate the model? Which parameters are likely to require this?
Figure 5: Illustrative design-oriented conceptual model

State 1 (Model entry point): Alive, relapse-free, on chemo (max 6 months sojourn)
- Chemotherapy & associated costs (dependent on sojourn time and compliance)
- AE costs
- HRQoL1 (age-independent)
- QALY loss for AEs

State 2: Alive, relapse-free, in follow-up (up to 48 months)
- Follow-up tests/appointment costs (dependent on sojourn time and compliance)
- HRQoL1 (age-independent)

State 3: Cured
- No further health system costs
- HRQoL1 (return to healthy population status)

State 4: Alive, post-relapse, active or supportive care
- Proportion active/palliative tx (P1)
- Costs active tx and supportive care (dependent on P1 and TTE5 in subgroup)
- HRQoL2 for active tx subgroup
- QALY loss for AEs due to active tx
- HRQoL3 for supportive care subgroup

State 5 (Model exit point): Dead
- Absorbing state
- No cost of death

TTE = time to event; AE = adverse event
Modelling clinical outcomes

- Which outcomes are needed by the decision-maker and how will they be estimated by the model?
- How should trial evidence be extrapolated over time?
- If final outcomes are not reported within the trials, what evidence is available concerning the relationship between intermediate and final outcomes? How might this information be used to inform the analysis of available evidence?
- How will the impact(s) of treatment be simulated? How will this directly/indirectly influence costs and health outcomes? What alternative choices are available?

Modelling approach

- Which methodological approach (e.g. state transition, patient-level simulation) is likely to be most appropriate? Why?
- Is the proposed modelling approach feasible given available resources for model development?
- How does the approach influence the way in which certain parameters are defined? What alternatives are available (e.g. time-to-event rates or probabilities)?
- Does the proposed modelling approach influence the level of depth possible within certain parts of the model?

Adherence to a health economic reference case

- Will the proposed model meet the criteria of the reference case specific to the decision-making jurisdiction in which the model will be used? If not, why should the anticipated deviations be considered appropriate?

Simplifications and abstractions

- Have any relevant events, costs or outcomes been purposefully omitted from the proposed model structure? Why? For what reason(s) may these omissions be considered appropriate?
- Are there any parts of the disease or treatment pathways that have been excluded altogether? Why?
- What is the expected impact of such exclusion/simplification decisions? Why?
- What are the key structural simplifications? How does the design-oriented model structure differ from the problem-oriented conceptual models? Why should these deviations be considered appropriate or necessary? What is the expected direction and impact of these exclusions on the model results?
Box 4: Recommendations for practice – design-oriented conceptual models

- The design-oriented conceptual model should be developed initially prior to the development of the final implementation model. It may, however, be revisited and modified within an iterative process during the development of the quantitative model.

- Model development involves making a large number of decisions and judgements. Not every decision or judgement made during model development will be important. The key decisions are likely to be those whereby the implemented model clearly deviates from the problem-oriented models (e.g. a part of the system is excluded) or whereby several alternative choices exist but none of which are clearly superior (i.e. structural uncertainties). These decisions should be clearly documented and reported.

- The sources of evidence used to inform model structure and the methods through which this information is elicited should be clearly reported.

- Where possible, alternative model development choices drawn out at this stage should be later tested using the quantitative model to assess their impact upon the model results. This will not however always be possible or feasible.

Evidence sources to inform conceptual models

A number of potential evidence sources may be useful for informing these types of conceptual model. Whilst the evidence requirements for any model will inevitably be broader than that for traditional systematic reviews of clinical effectiveness, the task of obtaining such evidence should remain a systematic, reproducible process of enquiry. Possible sources of evidence to inform conceptual models include: (1) clinical input; (2) existing systematic reviews; (3) clinical guidelines; (4) existing efficacy studies; (5) existing economic evaluations or models, and; (6) routine monitoring sources. Table 1 sets out some pragmatic concerns which should be borne in mind when using these evidence sources to inform conceptual model development.
### Table 1: Roles and concerns regarding the use of evidence to inform alternative model structures

<table>
<thead>
<tr>
<th>Existing economic evaluations / models</th>
<th>Expert input (including clinicians and potentially patients/service users)</th>
<th>Clinical guidelines / previous TA guidance / local treatment protocols</th>
<th>Empirical clinical studies and reviews (e.g. RCTs, cohort studies)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Principal role(s) in conceptual model development</strong></td>
<td><strong>To apply previously developed model structure to the current decision problem under consideration</strong></td>
<td><strong>To inform problem-oriented conceptual model development</strong></td>
<td><strong>To identify available evidence to inform relationships between intermediate and final endpoints</strong></td>
</tr>
<tr>
<td>• To use existing economic analyses to highlight key evidence limitations</td>
<td>• To use existing economic analyses to highlight key evidence limitations</td>
<td>• To scrutinise the credibility of alternative model structures</td>
<td>• To investigate what evidence is available</td>
</tr>
<tr>
<td>• To identify possible options for model development decisions</td>
<td>• To identify possible options for model development decisions</td>
<td>• To elucidate uncertainty regarding geographical variation</td>
<td>• To identify existing treatment/management pathways</td>
</tr>
<tr>
<td>• To identify relevant treatment pathways</td>
<td>• To identify relevant treatment pathways</td>
<td>• To highlight gaps in the existing evidence base</td>
<td>• To highlight gaps in the existing evidence base</td>
</tr>
<tr>
<td><strong>Issues and caveats associated with use</strong></td>
<td><strong>Seek input from more than one health professional to capture the spectrum of clinical opinion</strong></td>
<td><strong>Current practice may have evolved since publication of guidance</strong></td>
<td><strong>Potential reliance on the availability of evidence rather than the structure of the problem</strong></td>
</tr>
<tr>
<td>• Publication or other forms of dissemination of an existing model does not guarantee that the previous model was either appropriate or credible.</td>
<td>• Use multiple experts located in different geographical locations</td>
<td>• Such evidence sources may not provide sufficient detail to inform the current decision problem</td>
<td>• Differences between studies may suggest competing theories regarding (a) the nature of the disease process and (b) the relevance of particular events. This is not a problem as such but should be drawn out during conceptual model development.</td>
</tr>
<tr>
<td>• Advances in knowledge may render an existing model redundant</td>
<td>• There exists a trade-off between seeking support from individuals with considerable expertise and standing (may not have much time but more experience/knowledge) and less experienced clinicians (may have more time to engage but lesser knowledge of evidence base).</td>
<td>• Local protocols may not reflect geographical variations between centres</td>
<td>• Treatments and comparators may reflect historical rather than current or best practice</td>
</tr>
<tr>
<td>• There may exist a gap between the decision problem that the model was developed to address and the current decision-problem under consideration</td>
<td>• Health professionals cannot be completely objectively detached from the system the model intends to represent</td>
<td>• Local protocols and guidelines may not be evidence-based</td>
<td>• There may exist a gap between what should happen and what does in happen in clinical practice</td>
</tr>
<tr>
<td>• There may exist a gap between what should happen and what does in happen in clinical practice</td>
<td>• May be difficult to distinguish between conflict and geographical variations</td>
<td>• Potential conflicts of interest</td>
<td></td>
</tr>
<tr>
<td>• Potential conflicts of interest</td>
<td>• Potential ethical restrictions</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Potential reliance on the availability of evidence rather than the structure of the problem</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Discussion

This paper has set out a view of the model development process as one which is centred around the concept of uncertainty and choice. This process may be best characterised as a series of decisions concerning (a) what should be included in the model, (b) what should be excluded, and (c) how those phenomena that are included should be conceptually and mathematically represented. The unavoidable need to make such decisions has important implications for the interpretation of models, as none will be perfect, but several may credible, acceptable or adequate. However, in order for these judgements of credibility to be made, the underlying conceptual basis of models must be made clear. Only through the explicit use of conceptual models can deviations and simplifications be assessed, debated and agreed. The paper then moves on to propose a generalised approach for the development and reporting of conceptual models, with particular emphasis placed on the difference between problem-oriented and design-oriented models. These conceptual model forms are interrelated but serve different purposes during model development. The paper concludes with a discussion of the potential roles of alternative sources of evidence in informing conceptual model development.
References


